Showing results (31-40 of 44) with videos related to
Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patientsFrancisco Chung, Jun Lu, Brian D Palmer, et al.Pharmaceuticals (Basel, Switzerland)|September 23, 2022
Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines Expressing Either Murine or Human IDO1 or TDO2Sofian M Tijono, Brian D Palmer, Petr Tomek, et al.Oncology Research|February 24, 2006
A comparison of the ability of DMXAA and xanthenone analogues to activate NF-kappaB in murine and human cell linesSee-Tarn Woon, Charu B Reddy, Catherine J Drummond, et al.Journal of Medicinal Chemistry|July 10, 2007
Synthesis and biological activity of azido analogues of 5,6-dimethylxanthenone-4-acetic acid for use in photoaffinity labelingBrian D Palmer, Kimiora Henare, See-Tarn Woon, et al.Cancer Research|July 20, 2007
The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytesAfrica Wallace, David F LaRosa, Veena Kapoor, et al.Analytical and Bioanalytical Chemistry|January 15, 2013
Formation of an N-formylkynurenine-derived fluorophore and its use for measuring indoleamine 2,3-dioxygenase 1 activityPetr Tomek, Brian D Palmer, Jack U Flanagan, et al.Cell Communication and Signaling : CCS|November 24, 2018
Imprinted and ancient gene: a potential mediator of cancer cell survival during tryptophan deprivationPetr Tomek, Shanti K Gore, Chloe L Potts, et al.FEBS Letters|February 20, 2014
Connexin hemichannel induced vascular leak suggests a new paradigm for cancer therapyJie Zhang, Simon J O'Carroll, Kimiora Henare, et al.Neoplasia (New York, N.Y.)|August 4, 2009
Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404)Liang-Chuan S Wang, Lotte Thomsen, Rachel Sutherland, et al.Anticancer Research|March 14, 2007
NF-kappaB-independent induction of endothelial cell apoptosis by the vascular disrupting agent DMXAASee-Tarn Woon, Sandy S C Hung, Derek C F Wu, et al.Pageof 5